Loading Events

« All Events

  • This event has passed.

AI Digital Biology (ADIBio) Revolution Series

June 3 @ 8:30 am - 12:00 pm

To continue the great interest we received from our last AI Digital Biology (AIDBio) Labs Revolution event at JPM (600+ registrations, only able to receive the first 200 attendees) hosted by PwC, we invite you to join us for this 3rd edition. Connect with leading AI experts, pharma/biotech industry professionals, academics, and investors through real-world use cases. Explore the profound impact that AI Digital Biology has on reshaping the life sciences economy through modeling, computational biology, omics data, and synthetic biology. Come to discuss and initiate potential partnerships that can accelerate drug R&D for the benefit of patients.

Speakers and panelists:

Pr. Trey Ideker (UCSD) Dr. Trey Ideker is a Professor in the Departments of Medicine, Bioengineering and Computer Science at UC San Diego. Additionally, he is the Director or Co-Director of the National Resource for Network Biology (NRNB), the Cancer Cell Map Initiative (CCMI), the Psychiatric Cell Map Initiative (PCMI), and the UCSD Bioinformatics PhD Program, and former Chief of Genetics in the Department of Medicine. He is a pioneer in the mapping and analysis of biological networks and is a founding developer of the Cytoscape network analysis environment. Using these tools and advances in deep learning, the Ideker laboratory seeks to create artificially intelligent models of cancer and neuropsychiatric diseases for the translation of patient data to precision diagnosis and treatment.

Alex Aravanis (CEO at Moonwalk, former CTO Illumina, Co-Founder of Grail), Dr.Alex Aravanis is the CEO and co-founder of Moonwalk Biosciences, Inc. Before founding Moonwalk, Alex served as the Chief Technology Officer and Head of Research and Product Development at Illumina. In this role, he led the research and product development programs, launching the industry’s leading products for genomics-based research and clinical applications, including whole genome sequencing, comprehensive genomic profiling of cancer, COVID-Seq, and advanced AI tools for interpreting genomic information.

Alex is an experienced entrepreneur involved in founding several start-ups in life sciences and healthcare. He co-founded GRAIL Bio and served as Chief Scientific Officer and Head of R&D, where he led the development of its multi-cancer early detection test. Prior to GRAIL, Alex was the Senior Director of R&D at Illumina, where he developed technologies such as clinical assays for RNA and DNA analysis from fixed tissues, whole exome analysis, single cell transcriptomics, and liquid biopsy using cell-free nucleic acids.

Alex earned a BS in Electrical Engineering and Computer Science, with a minor in Physics, from the University of California, Berkeley, and an MS, PhD in Electrical Engineering, and an MD from Stanford University. He holds more than 30 pending and issued patents and has numerous peer-reviewed publications. Alex also serves on various Scientific Advisory Boards for biotech startups.

Mike Varney (TNL advisor, former Head R&D at Genentech), Dr. Mike Varney is a pioneer drug discoverer and biotech leader. As one of the original fifteen employees at Agouron, a biotech based in San Diego, he built a team that developed protein-structure based design, a novel approach to drug discovery that is utilized globally by drug discovery teams today. In 1997, the Agouron team launched Viracept, an HIV protease inhibitor that achieved the highest first year launch sales of any biotech product at the time. Dr. Varney’s leadership at Agouron resulted in the discovery of a number of currently marketed anti-cancer agents including Xalkori and Inlyta, a drug that won the American Chemical Society’s Heroes of Chemistry Award in 2018.
In 2005, Dr Varney was recruited to Genentech, the US based R&D organization in Roche, to expand the organization’s drug discovery capabilities to include small molecules. Focused on agility and pioneering science, Varney built a team-based organization that today produces more that 40% of Genentech’s development portfolio including the marketed anticancer agents Erivedge and Cotellic
In 2015, Dr Varney was appointed Executive Vice President and Head of Genentech’s Research and Early Development (gRED) and a member of the Roche Corporate Executive Committee in Basel. In this role, he was responsible for all aspects of gRED innovation, drug discovery and drug development. Varney also focused on building a team-based culture empowered to clear the path to patients. Under his leadership, gRED teams discovered and developed successful medicines that include Venclexta with AbbVie, the first bcl-2 inhibitor and Polivy, an antibody drug conjugate for the treatment of DLBCL. Pioneering molecules in the clinic include Mosunetuzumab, a bispecific antibody targeting CD20, and GDC-9545, a next generation estrogen receptor degrader. Dr. Varney retired from Genentech in July 2020, leaving a diversity of drug platform types that includes personalized therapeutic vaccines and cellular therapies.
Dr. Varney holds a B.S. in Chemistry from the University of California, Los Angeles, and a Ph.D. in synthetic organic chemistry from the California Institute of Technology, and was an American Cancer Society postdoctoral fellow at Columbia University.
Dr. Varney is currently an advisor to the Biotech and Pharma world and is a Board member of both public and private companies.

Abraham Heifets (CEO at Atomwise) Dr. Abraham Heifets is the CEO of Atomwise, which uses artificial intelligence to help discover new medicine. Abraham was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to help plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched high-performance data processing at IBM’s T.J. Watson Research Center and contributed to the artificial intelligence system of the world-champion robotic soccer team at Cornell University, from which he holds two previous degrees. Abraham has presented his work at the National Institutes of Health, the American Chemical Society, and the Association for the Advancement of Artificial Intelligence. He is an author on 19 papers, patents, and patent applications.

Nick Edwards (CEO at ReadySetPotato) Dr. Nick Edwards is an Entrepreneur-in-Residence at UC San Diego and CEO at Potato, where he’s building AI tools to help biologists design reproducible wet lab and computational protocols. Nick holds a PhD in neuroscience and is passionate about helping science improve our world through new tools and community. In his free time, he is the creator, host, and producer of the “Once a Scientist…” podcast, where he interviews scientists across industries about their lives and careers to highlight the diverse career options for scientists. He’s also intimately involved in the San Diego startup ecosystem, as a startup mentor and co-founder/organizer of the Bio x AI x SD community.

Reza Rassool (Chair at KWAAI) Reza Rassool is the Founder and Chair of Kwaai.ai, a developer community dedicated to democratizing AI and creating a Personal AI OS. As the former CTO of RealNetworks, he pivoted the company from its streaming media roots to become a leader in AI. Reza is a serial start-up professional with a history of creating over $1 billion in value through successful exits. He is an innovator with 27 granted US patents and 75 in WIPO, and has extensive expertise in computer vision, edge AI, biomedical devices, hybrid cloud, social gaming, agronomy, and more. Reza’s career includes roles as a founding employee at Zya and Widevine Technologies (both sold to Google), Director of Software at Second Sight (IPO 2014), and DSP Consultant at Advanced Bionics. He developed the Lightworks NLE, a product that won both a technical Oscar and an Emmy. Reza holds deep experience in C/C++, DSP, embedded, mobile, and cloud platforms, and is skilled in bringing projects in on time and under budget using methodologies like Agile. He has authored numerous technical articles and participated in standards bodies.

Ash Damle (CTO/AI at TNL, MIT) Ash Damle is a healthcare and AI entrepreneur, investor, and advisor, having helped raise over $100 million in funding and founded multiple startups aimed at improving societal health. As a technologist and data scientist, Ash focuses on the application of big data to health and its intersection with design, working with organizations across the United States, China, UK, Canada, Australia, France, Germany, India, and Japan. He has collaborated with leading venture capital firms such as Sandbox Industries, Intel Capital, and Khosla Ventures. Ash has founded companies including WithMe Health, excelera.health, Lumiata, and DeepAffects, and actively advises and invests in healthcare and AI companies like CareLoop, LoopHealth, PeerWell, MyoKardia, Ellipsis Health, NuBiome, and ExtraaEdge. Ash is a frequent speaker at conferences such as Health Datapalooza, Health 2.0, and MIT AI. He holds degrees in Computer Science and Mathematics from MIT, has published numerous papers, and received patents in real-time unstructured semantic analysis.

Jeff Guise (Partner at Eversheds) Dr. Jeffrey Guise is a patent prosecutor and litigator with over 25 years of experience, partnering with clients to build, manage, and protect their intellectual property (IP) portfolios globally. Holding a Ph.D. in molecular biology and immunology, Jeff primarily assists start-up and mid-market pharmaceutical, biotech, and medical technology companies in building, enforcing, and monetizing their patent portfolios. He also handles IP-related transactional matters, IP acquisition and licensing, non-infringement and validity opinions, freedom to operate analyses, and invention records management. Jeff’s technical expertise spans biotechnology, medical diagnostics, pharmaceutical, immunology, genetic engineering, genomics, proteomics, bioinformatics software, and more. He has enforced IP through litigation, including pre-trial and trial experience, and has successfully tried cases in several US district courts, courts of appeals, and the US Patent and Trademark Office.

Khai Pham, MD/PHD (AI) (CEO and Founder of TNL). Dr. Khai Minh Pham, an innovative entrepreneur and leading expert in Distributed AI, combines his medical (MD) and AI (PhD) expertise from Sorbonne University. He is the founder of Macro-connectionist Reasoning AI (MRAI), a unified AI framework that diverges from traditional neural networks by focusing on neuron assemblies. His first AI company, utilizing MRAI, served clients like Amex and Bank of America and was acquired for $637 million by E.piphany. The second generation of MRAI led to his second company, ThinkingNode.Life, which develops human digital cell clones for predictive and preclinical testing. Khai is also a founding advisory board member of Kwaai, a non-profit AI research lab. He has spoken at numerous conferences, including the Kwaai Summit, AIDBio Labs @ JPM, SCaLE 21x, and Bio Investor Forum. Khai has published several scientific papers, received international grants, and taught AI at LISH-CNRS. He holds an MD and PhD from Sorbonne University and has received several accolades, including an entrepreneur award from BP.

ThinkingNode.Life (TNL) is the first AI Digital Cell Clone Factory that can generate mechanistic digital human cell clones within an hour using ‘gene expression data. This allows the prediction and the understanding of the impacts of molecules or drugs on any human cell of interest. Providing a mechanistic way to identify novel disease-targets and to simulate each drug in various R&D phases, TNL brings a decisive advantage for developing both first-in-class and best-in-class drugs. This impacts the entire drug R&D value chain in multiple ways.

Details

Date:
June 3
Time:
8:30 am - 12:00 pm
Event Categories:
, ,
Website:
https://www.eventbrite.com/e/ai-digital-biology-adibio-revolution-series-tickets-883069262937

Venue

1100 Market St
1100 Market St
San Diego, CA 92101 United States
+ Google Map

Details

Date:
June 3
Time:
8:30 am - 12:00 pm
Event Categories:
, ,
Website:
https://www.eventbrite.com/e/ai-digital-biology-adibio-revolution-series-tickets-883069262937

Venue

1100 Market St
1100 Market St
San Diego, CA 92101 United States
+ Google Map